Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Ice bath timing may boost athlete recovery, new study suggests

NCT ID NCT06698237

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 15, 2026 · Updated 2 times

Summary

This study looks at whether taking a cold bath right after exercise or waiting a bit helps athletes recover better. Twelve healthy athletes will do intense workouts, then take a cold bath at different times. Researchers will measure muscle strength and blood amino acid levels to see which timing works best.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

12 people

The number who actually took part.

Started

Dec 2024

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 40 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria To be eligible to participate in this study, a participant must meet all the following criteria: 1. Healthy adult between 18 - 40 years (inclusive). 2. Individual with a BMI between \>18.5 and \<30 kg/m2 (inclusive). 3. Individual who is in good general health (no uncontrolled diseases or conditions). 4. individual with a history of regular resistance training ≥2 per week for the past six-months. 5. Individual who is currently competing at the varsity, provincial, national or international level in their respective sport. 6. Individual who is free from any musculoskeletal injuries and/or conditions that might affect their ability to perform resistance exercises or undergo cold-water immersion. 7. Individual who has maintained stable use of medication and/or supplements, stable dietary and lifestyle habits, and stable body weight (weight loss or gain \<3 kg), for the last three-months prior to screening. 8. Individual who agrees to maintain usual training habits between sessions. Exclusion Criteria 1. Individual who is lactating, pregnant or planning to become pregnant during the study. 2. Females with irregular menstrual cycles (defined as outside 24-38 days cycle range, based on self-reports). 3. Individual who adheres to a diet (e.g., vegan diet) that restricts consumption of dairy products. 4. Has a known sensitivity, intolerability, or allergy to any of the study products or their excipients (i.e., lactose intolerant). 5. Weight loss or gain \> 3 kg in the 3 months prior to study visit 1. 6. Currently or planning to be on a weight loss regimen during the study. 7. Recent (within 2 weeks of screening visit) history of an episode of acute GI illness such as nausea/vomiting or diarrhea. 8. Have a history of irritable bowel disease (IBS), inflammatory bowel disease (IBD, including ulcerative colitis and Crohn's disease), functional constipation or diarrhea (defined by the Rome IV diagnostic criteria), celiac disease, malabsorption, gastroparesis, diverticulosis, gastric or duodenal ulcers, pancreatitis, or eating disorder; or have a history of intestinal surgery (excluding appendectomy or herniorrhaphy) or bariatric surgery. 9. Have an abnormality or obstruction of the gastrointestinal tract precluding swallowing (e.g., dysphagia) and/or digestion (e.g., history of bowel obstruction). 10. Participated in upper gastrointestinal endoscopy and/or colonoscopy or preparation within 3 months prior to screening visit. 11. Diagnosed with hypercholesterolemia or hypertriglyceridemia (i.e., elevated fasting low- density lipoprotein (LDL) (≥ 135 mg·dL-1; ≥ 3.5 mmol·L-1) or elevated triglycerides (≥ 150 mg·dL-1; ≥1.7 mmol·L-1). 12. Has a history of heart disease/cardiovascular disease, uncontrolled hypertension (≥ 140 systolic or ≥ 90 diastolic mmHg), kidney disease (dialysis or renal failure), hepatic impairment or disease. 13. Is Type I or Type II diabetic or pre-diabetic \[i.e., elevated fasting blood glucose levels (≥ 100 mg·dL-1; ≥ 5.6 mmol·L-1) and/or elevated hemoglobin A1c (≥ 6.0%)\]. 14. Has a history of liver or gallbladder disease or stomach ulcers. 15. Has a positive medical history of unstable thyroid disease, previously diagnosed major affective disorder, psychiatric disorder that required hospitalization in the prior year, immune disorders and/or immunocompromised (e.g., HIV/AIDS). 16. Diagnosed with cancer (except localized skin cancer without metastases or in situ cervical cancer) within 5 years prior to the screening visit, or any clinically significant disease or disorder which, in the opinion of the investigator, may either put the potential participant at risk because of participation in the study, or influences the results or the potential participant's ability to participate in the study. 17. Major surgery in 3 months prior to screening or planned major surgery during the study. 18. History of alcohol or substance abuse (including cannabinoids) in the 12 months prior to screening (including having been hospitalized for such in an in-patient or out-patient intervention program). 19. Current or previous tobacco use within the last 6 months. 20. Self-report of blood donation totaling between 101 mL to 449 mL of blood within 30 days prior to screening or a blood donation of more than 450 mL within 56 days prior to baseline. 21. Self-report of donating plasma (e.g., plasmapheresis) within 14 days prior to screening. 22. Any other active or unstable medical conditions or use of medications/supplements/therapies that, in the opinion of the investigator, may adversely affect the participant's ability to complete the study or its measures or pose a significant risk to the participant.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aminoacidemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Motor Activity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • McGill University

    Montreal, Quebec, H2W 1S4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.